Logo

Samsung Bioepis Reports Results of Post-Hoc Analysis from P-III Study of Byooviz (biosimilar- ranibizumab) for the Treatment of nAMD

Share this
Samsung Bioepis Reports Results of Post-Hoc Analysis from P-III Study of Byooviz (biosimilar- ranibizumab) for the Treatment of nAMD

Samsung Bioepis Reports Results of Post-Hoc Analysis from P-III Study of Byooviz (biosimilar- ranibizumab) for the Treatment of nAMD

Shots:

  • The P-III study evaluates Byooviz (0.5 mg- IVT) vs ranibizumab in 634 patients with nAMD. The results will be presented at EURETINA 2021
  • The 1EPs are changed from baseline in BCVA @8wks. and change in CST @4wks. with both EPs- followed by 52wks. The post-hoc analysis showed that the baseline age- BCVA- CST- and total lesion size were identified to be associated with the visual acuity & anatomical outcomes
  • In subgroup analysis- similar visual outcomes of 2 products in change from baseline in BCVA in multiple subgroups were observed & support an equivalent clinical efficacy. Byooviz is an effective & valuable treatment option for nAMD patients globally

| Ref: Samsung Bioepis | Image: PharmaLive

Click here to­ read the full press release 

Tuba

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions